Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB).
Vikas OstwalSarika MandavkarPrabhat BhargavaSujay SrinivasAkhil KapoorOmshree ShettySadhana KannanDeepali ChauguleRajshree PatilManali ParulekarChaitali NashikkarSuman Kumar AnkathiAkshay Dwarka BahetiDaksha MehtaRajiv Kumar KaushalSubhash C YadavAekta ShahShraddha PatkarMahesh GoelAnant RamaswamyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The combination of GC and trastuzumab achieved its primary end point of improving PFS compared with historical data in the treatment-naïve HER2-positive BTC. Evaluating additional mutations such as TP53 and PIK3CA along with HER2 testing may help to preferentially select patients for anti-HER2 therapy in the future (Clinical Trial Registry India number: CTRI/2019/11/021955).
Keyphrases
- epidermal growth factor receptor
- open label
- phase ii study
- clinical trial
- locally advanced
- tyrosine kinase
- advanced non small cell lung cancer
- end stage renal disease
- squamous cell carcinoma
- endothelial cells
- phase ii
- newly diagnosed
- phase iii
- randomized controlled trial
- stem cells
- peritoneal dialysis
- mesenchymal stem cells
- double blind
- prognostic factors
- combination therapy
- replacement therapy
- big data
- patient reported outcomes
- electronic health record
- cross sectional
- current status
- rectal cancer
- pluripotent stem cells
- bone marrow
- induced pluripotent stem cells
- gas chromatography